Significance of genetic modifiers of hemoglobinopathies leading towards precision medicine

• Published in: Scientific reports Vol. 11; no. 1; p. 20906
• Main Authors: Hariharan, Priya, Gorivale, Manju, Sawant, Pratibha, Mehta, Pallavi, Nadkarni, Anita
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 22.10.2021; Nature Publishing Group; Nature Portfolio
• Subjects: 631/208; 631/337; 692/4017; 692/699; alpha-Thalassemia - genetics; Anemia, Sickle Cell - genetics; beta-Thalassemia - genetics; Blood diseases; Child; Child, Preschool; gamma-Globins - genetics; Genes, Modifier - genetics; Genetic Loci - genetics; Genetic Markers - genetics; Genetic variability; Genetics; Genotype; Hemoglobinopathies - genetics; Hemoglobinopathy; Homozygotes; Humanities and Social Sciences; Humans; multidisciplinary; Phenotype; Phenotypes; Polymorphism, Single Nucleotide - genetics; Precision medicine; Precision Medicine - methods; Promoter Regions, Genetic - genetics; Science; Science (multidisciplinary); Sickle cell disease; Single-nucleotide polymorphism; Thalassemia
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-021-00169-x

Hemoglobinopathies though a monogenic disorder, show phenotypic variability. Hence, understanding the genetics underlying the heritable sub-phenotypes of hemoglobinopathies, specific to each population, would be prognostically useful and could inform personalized therapeutics. This study aimed to evaluate the role of genetic modifiers leading to higher HbF production with cumulative impact of the modifiers on disease severity. 200 patients (100 β-thalassemia homozygotes, 100 Sickle Cell Anemia), and 50 healthy controls were recruited. Primary screening followed with molecular analysis for confirming the β-hemoglobinopathy was performed. Co-existing α-thalassemia and the polymorphisms located in 3 genetic loci linked to HbF regulation were screened. The most remarkable result was the association of SNPs with clinically relevant phenotypic groups. The γ-globin gene promoter polymorphisms [− 158 C → T, + 25 G → A],BCL11A rs1427407 G → T, − 3 bp HBS1L-MYB rs66650371 and rs9399137 T → C polymorphisms were correlated with higher HbF, in group that has lower disease severity score (P < 0.00001), milder clinical presentation, and a significant delay in the age of the first transfusion. Our study emphasizes the complex genetic interactions underlying the disease phenotype that may be a prognostic marker for predicting the clinical severity and assist in disease management.